Caple Kim 4

What Happened

• Kim Caple, a director of Castle Biosciences (CSTL), was granted 11,766 restricted stock units (RSUs) on May 28, 2026. The Form 4 reports an acquisition of 11,766 derivative units at $0.00 (i.e., an RSU award rather than a cash purchase or sale).

Key Details

• Transaction date and type: 2026-05-28 — Grant / Award (derivative RSUs).
• Amount: 11,766 RSUs; reported acquisition price $0.00; immediate reported value $0.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes: F1 — each RSU equals the right to receive one share of common stock; F2 — the RSUs vest in full on the earlier of (a) the one‑year anniversary (around May 28, 2027) or (b) the day immediately preceding the next Annual Meeting of Stockholders following the grant.
• Filing timeliness: no late‑filing indication provided in the supplied data.

Context

• RSUs are compensation awards that convert to actual shares upon vesting; they do not represent immediate cash outlay by the insider and typically reflect standard director compensation rather than an open‑market purchase. This award should be viewed as a grant of future potential shares subject to the stated vesting conditions.